CD276 and glioblastoma: In 2019, Nehama et al. verified that CAR-T targeting B7-H3 release effective factors such as IFN-γ and IL-2 and control the growth of B7-H3+ human GBM cell lines and neurospheres (Nehama et al., 2019).